Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Conservation of cell-intrinsic immune responses in diverse nonhuman primate species.

Gaska JM, Parsons L, Balev M, Cirincione A, Wang W, Schwartz RE, Ploss A.

Life Sci Alliance. 2019 Oct 24;2(5). pii: e201900495. doi: 10.26508/lsa.201900495. Print 2019 Oct.

2.

Master of disguise: hepatitis delta virus packaging and spread facilitated by diverse viral envelope proteins.

Maya S, Ploss A.

Hepatology. 2019 Aug 29. doi: 10.1002/hep.30922. [Epub ahead of print]

PMID:
31465549
3.

Hepatitis E Virus Replication.

LeDesma R, Nimgaonkar I, Ploss A.

Viruses. 2019 Aug 6;11(8). pii: E719. doi: 10.3390/v11080719. Review.

4.

Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System.

Winer BY, Gaska JM, Lipkowitz G, Bram Y, Parekh A, Parsons L, Leach R, Jindal R, Cho CH, Shrirao A, Novik E, Schwartz RE, Ploss A.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30815. [Epub ahead of print]

PMID:
31206195
5.

Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus.

Gaska JM, Balev M, Ding Q, Heller B, Ploss A.

Elife. 2019 May 10;8. pii: e44436. doi: 10.7554/eLife.44436.

6.

Decoding type I and III interferon signalling during viral infection.

Mesev EV, LeDesma RA, Ploss A.

Nat Microbiol. 2019 Jun;4(6):914-924. doi: 10.1038/s41564-019-0421-x. Epub 2019 Apr 1. Review.

7.

Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies.

Gaska JM, Ding Q, Ploss A.

Methods Mol Biol. 2019;1911:481-503. doi: 10.1007/978-1-4939-8976-8_33.

8.

Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses.

Douam F, Ziegler CGK, Hrebikova G, Fant B, Leach R, Parsons L, Wang W, Gaska JM, Winer BY, Heller B, Shalek AK, Ploss A.

Nat Commun. 2018 Nov 28;9(1):5031. doi: 10.1038/s41467-018-07478-2.

9.

Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais MA, Frankel AS, Chiriboga L, Cullen J, Nahass RG, Lutgehetmann M, Toettcher JE, Wiles MV, Schwartz RE, Ploss A.

Sci Transl Med. 2018 Jun 27;10(447). pii: eaap9328. doi: 10.1126/scitranslmed.aap9328.

10.

Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.

Douam F, Ploss A.

Trends Microbiol. 2018 Nov;26(11):913-928. doi: 10.1016/j.tim.2018.05.012. Epub 2018 Jun 19. Review.

11.

Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease.

Ding Q, Gaska JM, Douam F, Wei L, Kim D, Balev M, Heller B, Ploss A.

Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6310-E6318. doi: 10.1073/pnas.1803406115. Epub 2018 Jun 18.

12.

Identification of the Intragenomic Promoter Controlling Hepatitis E Virus Subgenomic RNA Transcription.

Ding Q, Nimgaonkar I, Archer NF, Bram Y, Heller B, Schwartz RE, Ploss A.

MBio. 2018 May 8;9(3). pii: e00769-18. doi: 10.1128/mBio.00769-18.

13.

Immunization with AgTRIO, a Protein in Anopheles Saliva, Contributes to Protection against Plasmodium Infection in Mice.

Dragovic SM, Agunbiade TA, Freudzon M, Yang J, Hastings AK, Schleicher TR, Zhou X, Craft S, Chuang YM, Gonzalez F, Li Y, Hrebikova G, Tripathi A, Mlambo G, Almeras L, Ploss A, Dimopoulos G, Fikrig E.

Cell Host Microbe. 2018 Apr 11;23(4):523-535.e5. doi: 10.1016/j.chom.2018.03.008.

14.

The use of humanized mice for studies of viral pathogenesis and immunity.

Douam F, Ploss A.

Curr Opin Virol. 2018 Apr;29:62-71. doi: 10.1016/j.coviro.2018.03.003. Epub 2018 Mar 28. Review.

15.

A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism.

Douam F, Fusil F, Enguehard M, Dib L, Nadalin F, Schwaller L, Hrebikova G, Mancip J, Mailly L, Montserret R, Ding Q, Maisse C, Carlot E, Xu K, Verhoeyen E, Baumert TF, Ploss A, Carbone A, Cosset FL, Lavillette D.

PLoS Pathog. 2018 Mar 5;14(3):e1006908. doi: 10.1371/journal.ppat.1006908. eCollection 2018 Mar.

16.

Hepatitis E virus: advances and challenges.

Nimgaonkar I, Ding Q, Schwartz RE, Ploss A.

Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):96-110. doi: 10.1038/nrgastro.2017.150. Epub 2017 Nov 22. Review.

PMID:
29162935
17.

A porcine model for chronic hepatitis E.

Nimgaonkar I, Ploss A.

Hepatology. 2018 Feb;67(2):787-790. doi: 10.1002/hep.29566. Epub 2018 Jan 1. No abstract available.

PMID:
28961321
18.

Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.

Douam F, Soto Albrecht YE, Hrebikova G, Sadimin E, Davidson C, Kotenko SV, Ploss A.

MBio. 2017 Aug 15;8(4). pii: e00819-17. doi: 10.1128/mBio.00819-17.

19.

Long-term hepatitis B infection in a scalable hepatic co-culture system.

Winer BY, Huang TS, Pludwinski E, Heller B, Wojcik F, Lipkowitz GE, Parekh A, Cho C, Shrirao A, Muir TW, Novik E, Ploss A.

Nat Commun. 2017 Jul 25;8(1):125. doi: 10.1038/s41467-017-00200-8.

20.

Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates.

Li D, Wang X, von Schaewen M, Tao W, Zhang Y, Heller B, Hrebikova G, Deng Q, Sun Q, Ploss A, Zhong J, Huang Z.

J Infect Dis. 2017 Jun 15;215(12):1824-1831. doi: 10.1093/infdis/jix180.

21.

Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.

Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F.

J Hepatol. 2017 Aug;67(2):246-254. doi: 10.1016/j.jhep.2017.03.027. Epub 2017 Apr 7.

22.

Single-cell tracking of flavivirus RNA uncovers species-specific interactions with the immune system dictating disease outcome.

Douam F, Hrebikova G, Albrecht YE, Sellau J, Sharon Y, Ding Q, Ploss A.

Nat Commun. 2017 Mar 14;8:14781. doi: 10.1038/ncomms14781.

23.

Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles.

Ding Q, Heller B, Capuccino JM, Song B, Nimgaonkar I, Hrebikova G, Contreras JE, Ploss A.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1147-1152. doi: 10.1073/pnas.1614955114. Epub 2017 Jan 17. Erratum in: Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4897.

24.

Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection.

Winer BY, Huang T, Low BE, Avery C, Pais MA, Hrebikova G, Siu E, Chiriboga L, Wiles MV, Ploss A.

Virology. 2017 Feb;502:63-72. doi: 10.1016/j.virol.2016.12.017. Epub 2016 Dec 19.

25.

Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.

Ding Q, von Schaewen M, Hrebikova G, Heller B, Sandmann L, Plaas M, Ploss A.

J Virol. 2017 Jan 31;91(4). pii: e01799-16. doi: 10.1128/JVI.01799-16. Print 2017 Feb 15.

26.

Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.

von Schaewen M, Dorner M, Hueging K, Foquet L, Gerges S, Hrebikova G, Heller B, Bitzegeio J, Doerrbecker J, Horwitz JA, Gerold G, Suerbaum S, Rice CM, Meuleman P, Pietschmann T, Ploss A.

MBio. 2016 Nov 8;7(6). pii: e01915-16. doi: 10.1128/mBio.01915-16.

27.

Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.

Li D, von Schaewen M, Wang X, Tao W, Zhang Y, Li L, Heller B, Hrebikova G, Deng Q, Ploss A, Zhong J, Huang Z.

J Virol. 2016 Nov 14;90(23):10486-10498. doi: 10.1128/JVI.01462-16. Print 2016 Dec 1.

28.

Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.

Bartucci M, Ferrari AC, Kim IY, Ploss A, Yarmush M, Sabaawy HE.

Front Cell Dev Biol. 2016 Jul 11;4:74. doi: 10.3389/fcell.2016.00074. eCollection 2016.

29.

Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Shirvani-Dastgerdi E, Schwartz RE, Ploss A.

Curr Opin Virol. 2016 Oct;20:1-10. doi: 10.1016/j.coviro.2016.07.009. Epub 2016 Aug 6. Review.

30.

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

Basta NE, Mahmoud AA, Wolfson J, Ploss A, Heller BL, Hanna S, Johnsen P, Izzo R, Grenfell BT, Findlow J, Bai X, Borrow R.

N Engl J Med. 2016 Jul 21;375(3):220-8. doi: 10.1056/NEJMoa1514866.

31.

Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.

Bartucci M, Ferrari AC, Kim IY, Ploss A, Yarmush M, Sabaawy HE.

Front Cell Dev Biol. 2016 Jun 23;4:64. doi: 10.3389/fcell.2016.00064. eCollection 2016. Erratum in: Front Cell Dev Biol. 2016;4:74.

32.

Generation of Human Liver Chimeric Mice for the Study of Human Hepatotropic Pathogens.

von Schaewen M, Hrebikova G, Ploss A.

Methods Mol Biol. 2016;1438:79-101. doi: 10.1007/978-1-4939-3661-8_5.

PMID:
27150085
33.

In vivo models of hepatitis B and C virus infection.

Winer BY, Ding Q, Gaska JM, Ploss A.

FEBS Lett. 2016 Jul;590(13):1987-99. doi: 10.1002/1873-3468.12157. Epub 2016 Apr 8. Review.

34.

Recent advances in understanding hepatitis C.

Douam F, Ding Q, Ploss A.

F1000Res. 2016 Feb 3;5. pii: F1000 Faculty Rev-131. doi: 10.12688/f1000research.7354.1. eCollection 2016. Review.

35.

Genetic Dissection of the Host Tropism of Human-Tropic Pathogens.

Douam F, Gaska JM, Winer BY, Ding Q, von Schaewen M, Ploss A.

Annu Rev Genet. 2015;49:21-45. doi: 10.1146/annurev-genet-112414-054823. Epub 2015 Sep 25. Review.

36.

Breaking the species barrier for hepatitis delta virus.

Winer BY, Ploss A.

Hepatology. 2016 Jan;63(1):334-6. doi: 10.1002/hep.28129. Epub 2015 Oct 29. No abstract available.

37.

Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.

Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, von Schaewen M, Heller B, Vercauteren K, Luxenburger E, Baktash YM, Vondran FW, Speerstra S, Awadh A, Mukhtarov F, Schang LM, Kirschning A, Müller R, Guzman CA, Kaderali L, Randall G, Meuleman P, Ploss A, Pietschmann T.

Hepatology. 2016 Jan;63(1):49-62. doi: 10.1002/hep.28111. Epub 2015 Oct 9.

38.

Editorial overview: Progress and challenges in modeling human viral diseases in vivo.

Ploss A, Walker C.

Curr Opin Virol. 2015 Aug;13:v-vii. doi: 10.1016/j.coviro.2015.07.004. Epub 2015 Jul 26. No abstract available.

39.

Determinants of hepatitis B and delta virus host tropism.

Winer BY, Ploss A.

Curr Opin Virol. 2015 Aug;13:109-16. doi: 10.1016/j.coviro.2015.06.004. Epub 2015 Jul 8. Review.

40.

Axillary artery cannulation provides balanced cerebral oxygenation.

Hillebrand J, Zheng Z, Ploss A, Herrmann E, Moritz A, Martens S.

Heart Vessels. 2016 Jul;31(7):1077-83. doi: 10.1007/s00380-015-0704-y. Epub 2015 Jun 26.

PMID:
26113457
41.

Novel Biomarkers Associated With the Outcome of Interferon-Based Hepatitis C Virus Therapy.

von Schaewen M, Ploss A.

Cell Mol Gastroenterol Hepatol. 2015 Apr 18;1(3):257-258. doi: 10.1016/j.jcmgh.2015.03.005. eCollection 2015 May. No abstract available.

42.

Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.

Scull MA, Shi C, de Jong YP, Gerold G, Ries M, von Schaewen M, Donovan BM, Labitt RN, Horwitz JA, Gaska JM, Hrebikova G, Xiao JW, Flatley B, Fung C, Chiriboga L, Walker CM, Evans DT, Rice CM, Ploss A.

Hepatology. 2015 Jul;62(1):57-67. doi: 10.1002/hep.27773. Epub 2015 Apr 15.

43.

Proteomic approaches to analyzing hepatitis C virus biology.

Douam F, Ploss A.

Proteomics. 2015 Jun;15(12):2051-65. doi: 10.1002/pmic.201500009. Epub 2015 May 5. Review.

44.

Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4.

Stoddard MB, Li H, Wang S, Saeed M, Andrus L, Ding W, Jiang X, Learn GH, von Schaewen M, Wen J, Goepfert PA, Hahn BH, Ploss A, Rice CM, Shaw GM.

MBio. 2015 Feb 24;6(2):e02518. doi: 10.1128/mBio.02518-14.

45.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M.

Nature. 2015 Mar 5;519(7541):87-91. doi: 10.1038/nature14264. Epub 2015 Feb 18.

46.

Modeling malaria in humanized mice: opportunities and challenges.

Siu E, Ploss A.

Ann N Y Acad Sci. 2015 Apr;1342:29-36. doi: 10.1111/nyas.12618. Epub 2015 Feb 11. Review.

PMID:
25678404
47.

Study of viral pathogenesis in humanized mice.

Gaska JM, Ploss A.

Curr Opin Virol. 2015 Apr;11:14-20. doi: 10.1016/j.coviro.2015.01.002. Epub 2015 Jan 22. Review.

48.

The impact of hepatitis C virus entry on viral tropism.

Ding Q, von Schaewen M, Ploss A.

Cell Host Microbe. 2014 Nov 12;16(5):562-8. doi: 10.1016/j.chom.2014.10.009. Epub 2014 Nov 12. Review.

49.

Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.

Lacek K, Urbanowicz RA, Troise F, De Lorenzo C, Severino V, Di Maro A, Tarr AW, Ferrara F, Ploss A, Temperton N, Ball JK, Nicosia A, Cortese R, Pessi A.

J Biol Chem. 2014 Dec 12;289(50):35015-28. doi: 10.1074/jbc.M114.591826. Epub 2014 Oct 23.

50.

Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, Winer BY, Gerges S, Vega K, Labitt RN, Donovan BM, Giang E, Krishnan A, Chiriboga L, Charlton MR, Burton DR, Baltimore D, Law M, Rice CM, Ploss A.

Sci Transl Med. 2014 Sep 17;6(254):254ra129. doi: 10.1126/scitranslmed.3009512.

Supplemental Content

Support Center